Read the announcement: To view or add a comment, sign in BREAKING NEWS: The Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) for the treatment of adults living with lupus nephritis, supported by positive Phase II and III trial results
Appearance pearly papule with surface telangiectasia (small visible vessels)
Bhattacharyya T, Walker M, Powers NR, Brunton C, Fine AD, Petkov PM, Handel MA (2019) Prdm9 and meiotic cohesin proteins cooperatively promote DNA double-strand break formation in mammalian spermatocytes
However, a pooled analysis of liraglutide trials demonstrated that blood pressure lowering occurs within two weeks of treatment initiation, suggesting other effects on vasculature beyond weight loss [36]
NICE guidelines recommend lifestyle modifications as foundational therapy, but many patients require additional pharmacological treatment to achieve glycaemic targets or clinically significant weight loss